Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Chief Accounting Officer | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,366 |
Ending reported balance
After 2026-03-02 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-02-27 · Exercise / conversion · Acquired 7,500 · Balance 26,068 F1: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. Row 2 · 2026-02-27 · Tax withholding · Disposed 3,262 · Balance 22,806 F2: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026. F3: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Row 3 · 2026-02-27 · Exercise / conversion · Acquired 550 · Balance 23,356 F4: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. Row 4 · 2026-02-27 · Tax withholding · Disposed 240 · Balance 23,116 F5: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026. F3: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Row 5 · 2026-03-02 · Sale · Disposed 750 · Balance 22,366 F6: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Exercise / conversion · Disposed 7,500 · Balance 0 F1: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,650 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Exercise / conversion · Disposed 550 · Balance 1,650 F4: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,442 |
Reported balance
After 2026-02-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-27 · Grant · Acquired 5,442 · Balance 5,442 F8: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. F9: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. F10: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $275.64 · Expires 2036-02-26 | Direct | 13,575 |
Reported balance
After 2026-02-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-27 · Grant · Acquired 13,575 · Balance 13,575 F7: The stock options vest in four equal annual installments beginning on February 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.
F2: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.
F3: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.
F4: 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026.
F5: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026.
F6: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.
F7: The stock options vest in four equal annual installments beginning on February 27, 2027.
F8: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
F9: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
F10: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,955 | $109.17 | $322,602.96 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 13 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,556 F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. F8 · price: The transaction was executed in multiple trades ranging from $108.9000 to $109.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 2,955 | $52.26 | $154,428.30 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 12 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. Read SEC document |
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,300 | $107.88 | $140,241.01 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 11 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,556 F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. F7 · price: The transaction was executed in multiple trades ranging from $107.6900 to $108.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 1,300 | $52.26 | $67,938.00 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 10 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. Read SEC document |
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,570 | $106.81 | $274,498.36 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 9 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,556 F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. F6 · price: The transaction was executed in multiple trades ranging from $106.3700 to $107.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 2,570 | $52.26 | $134,308.20 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 8 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. Read SEC document |
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,521 | $105.80 | $266,730.88 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 7 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,556 F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. F5 · price: The transaction was executed in multiple trades ranging from $105.3400 to $106.3100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 22, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 2,521 | $52.26 | $131,747.46 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 6 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. Read SEC document |
| May 19, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $52.26 | $0.00 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · derivative · entry 19 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share. F12 · derivative.exercise_date: 50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021. Read SEC document |
| May 19, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $52.26 | $0.00 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · derivative · entry 18 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires 2030-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share. F12 · derivative.exercise_date: 50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021. Read SEC document |
| May 19, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,428 | $95.08 | $325,936.98 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 5 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,556 F3 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates sales of 3,428 shares with a limit price of $95.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 19, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 12,500 | $95.04 | $1,188,061.25 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 4 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,984 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 19, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 12,500 | $52.26 | $653,250.00 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 3 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share. Read SEC document |
| May 19, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 12,500 | $95.05 | $1,188,125.00 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 2 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,984 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 19, 2023 Filed May 23, 2023 16:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 12,500 | $52.26 | $653,250.00 |
DisclosureSEC source: 0001801385-23-000004 · wf-form4_168487338437565.xml · nonDerivative · entry 1 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share. Read SEC document |
| February 28, 2023 Filed Feb 28, 2023 18:43 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantPerformance Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001801385-23-000002 · wf-form4_167762777317914.xml · derivative · entry 3 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. F5 · shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance metrics set by the Company's Compensation Committee for this award. F6 · derivative.exercise_date: If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025). F7 · derivative.expiration_date: If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire. F5 · derivative.underlying_shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance metrics set by the Company's Compensation Committee for this award. F5 · balance_after: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance metrics set by the Company's Compensation Committee for this award. Read SEC document |
| February 28, 2023 Filed Feb 28, 2023 18:43 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $81.91 | $0.00 |
DisclosureSEC source: 0001801385-23-000002 · wf-form4_167762777317914.xml · derivative · entry 2 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-28 F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2024. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 18:43 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 2,144 | $78.46 | $168,218.24 |
DisclosureSEC source: 0001801385-23-000002 · wf-form4_167762777317914.xml · nonDerivative · entry 1 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,984 F1 · shares: Represents tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2023. F2 · price: The closing price on February 24, 2023 of the Company's common stock on NASDAQ. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 21:25 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $63.55 | $0.00 |
DisclosureSEC source: 0001801385-22-000005 · wf-form4_164618791185342.xml · derivative · entry 2 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-28 F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2023. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 21:25 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 1,472 | $62.50 | $92,000.00 |
DisclosureSEC source: 0001801385-22-000005 · wf-form4_164618791185342.xml · nonDerivative · entry 1 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,128 F1 · shares: Represents tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2022. F2 · price: The closing price on February 25, 2022 of the Company's common stock on NASDAQ. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 29,400 | $0.00 Strike: $78.89 | $0.00 |
DisclosureSEC source: 0000899243-21-009163 · doc4.xml · derivative · entry 2 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 29,400 shares Expires 2025-02-26 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 26, 2022. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantCommon Stock | 19,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-009163 · doc4.xml · nonDerivative · entry 1 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 F1 · security: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022. F1 · shares: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022. F1 · price: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022. Read SEC document |
| January 31, 2020 Filed Feb 25, 2020 17:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $52.26 | $0.00 |
DisclosureSEC source: 0001209191-20-012615 · doc4.xml · derivative · entry 1 Romano Kathryn · CIK 0001801385 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: The options vest ratably over a four-year period beginning on January 20, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.